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community-dwelling elderly (the Bambuí Cohort
Study of Ageing)
Maria Lea Correa Leite1*, Joselia OA Firmo2, Antonio Ignacio Loyola Filho2,3 and Maria Fernanda Lima-Costa2,3Abstract
Background: Hypertension remains a major public health problem whose management is hampered by poor
persistence with pharmacological therapy. The aim of this study was to evaluate the association between
discontinuing antihypertensive drugs (AHDs) and the risk of cardiovascular mortality in the elderly.
Methods: A population-based prospective cohort study of all of the ≥60-year-old residents in Bambuí city (Brazil)
enrolled 1606 subjects (92.2%), of whom 1494 (93.0%) were included in this study. The use of AHDs was ascertained
annually in a real-clinical context, and time-varying AHD exposure was categorised as non-use, current use or
stopped. The predicted cardiovascular mortality rates were estimated using interval Poisson models for ungrouped
person-time data, taking into account current levels of systolic blood pressure (BP).
Results: The overall adjusted cardiovascular mortality risk ratio of AHD stoppers vs current users was 3.12 (95% CI:
2.35-4.15). There was a significant interaction with BP levels: the association between discontinuing AHDs and the
risk of cardiovascular mortality was stronger at higher systolic BP levels. The estimates of the risk of cardiovascular
mortality over the follow-up period were similar in AHD users and non-users, for whom AHDs were never prescribed.
Conclusion: Discontinuing AHDs increases the risk of cardiovascular mortality in the elderly. Misconceptions about
symptoms or drug-related adverse effects could underlie a subject’s decision to discontinue AHDs. Greater attention
should be paid to the choice of AHDs and informative action.
Keywords: Hypertension, Antihypertensive drugs, Mortality risk, ElderlyBackground
There is growing evidence that antihypertensive treatment
is beneficial in the elderly [1], but hypertension remains a
major public health problem whose prevalence is increasing
throughout the world with the ageing of the population [2].
The World Health Organization (WHO) estimated that at
least 50% of cardiovascular diseases and 75% of strokes re-
sult from high blood pressure (BP) [3]. Because of its high
prevalence and severe consequences, efforts have been
made worldwide to increase detection and control of exist-
ing arterial hypertension [4-6]. However, population-based* Correspondence: lea.correa@itb.cnr.it
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article, unless otherwise stated.cross-sectional studies have shown that the prevalence of
appropriate control of arterial pressure (that is, systolic and
diastolic BP below 140 and 90 mmHg, respectively) among
individuals treated with antihypertensive drugs ranges from
as little as about 40% in the USA [7], Mozambique [8] and
Brazil [9] to 66% in Canada [10].
The adequate control of hypertension is seriously ham-
pered by poor persistence with pharmacological therapy
[11], particularly among the elderly [12]. There are a num-
ber of published studies concerning the predictors of per-
sistence [13,14], and some data concerning the health and
economic consequences of non-adherence [15,16] but, to
the best of our knowledge, no attempt has yet been made
to quantify the impact of discontinuing antihypertensiventral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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in the elderly.
In Brazil, although free and widespread access to essen-
tial medicines standardized by the Unified National Health
System (SUS) is constitutionally guaranteed, it is still a
challenge to ensure complete therapeutic assistance. In
1998, the government approved the National Medicines
Policy [17] in an attempt to promote access to and the ra-
tional use of medicines. In 2002, the National Program of
Pharmaceutical Assistance to Arterial Hypertension and
Diabetes Mellitus was instituted in order to provide access
to essential medicines within the SUS [18]. However, a
lack of free access to hypertension medicines has been re-
ported to be mainly due to the unavailability in the public
sector [19]. Therefore, in 2004, the federal government in-
troduced the “Farmacia Popular do Brasil“ Program, estab-
lishing a co-payment scheme as a strategy for improving
access to medicines. People have consistently resorted to
this program to obtain essential medicines that they have
been unable to access in the public sector [20].
The aim of this study was to evaluate the association be-
tween the discontinuation of AHD use and the long-term
risk of CV mortality in a large population-based elderly
cohort in Brazil. The Bambuí Cohort Study of Ageing
dataset provided annual verification of AHD use and certi-
fied deaths along 11 years, and therefore offers a valuable
means of examining the relationship between AHD expos-
ure and mortality risk. Furthermore, the availability of data
concerning other variables, including repeated BP mea-
surements, makes it possible to control for different socio-
demographic, clinical, biological and lifestyle conditions.
Methods
Study design and population
The data come from the Bambuí Cohort Study of Ageing,
which involved a population-based cohort of older adults
in Bambuí, a city of approximately 15,000 inhabitants in
south-eastern Brazil. The main objective of the cohort
study was the examination of the consequences of the
double burden of non-communicable diseases and chronic
Chagas’ disease, an infection caused by the protozoan
Trypanosoma cruzi [21,22]. The study procedures have
been described in detail elsewhere [21]. Briefly, the baseline
cohort consisted of 1742 residents aged ≥60 years on 1
January 1997, who were identified by means of a complete
census in the city. Of these, 1606 (92.2%) participated in
the baseline survey, which consisted of a questionnaire de-
signed to collect data relating to socio-demographic vari-
ables, lifestyles, medical history and drug use, laboratory
tests (biochemical and hematological analyses), and physical
measurements (BP and anthropometric measures). All of
the interviewers and health technicians were certified after
training at a specialized center at the School of Medicine of
the Minas Gerais Federal University. The mean age of theparticipants was 69.3 years (range 60–95 years), and
60.0% were women. The follow-up was based on annual
interviews and the verification of death certificates, and
collected information concerning the current use of
medication.
The participants signed an informed consent form and
authorised the verification of death certificates. The
Bambuí Cohort Study of Ageing was approved by the
Ethics Committee of the Fundação Oswaldo Cruz, Brazil.
Source of mortality data
The analysis was based on the deaths occurring between
the time of study enrolment and 31 December 2007.
The deaths were reported by the next of kin during the
annual follow-up interview, and confirmed by the Brazilian
Mortality Information System (Sistema de Informações
sobre Mortalidade) with the permission of the Brazilian
Ministry of Health. Death certificates were obtained for
98.9% of the subjects. Deaths due to CV causes were de-
fined as those caused by hypertensive diseases, ischemic
heart diseases, pulmonary heart disease, cerebrovascular
diseases, diseases of arteries, arterioles and capillaries, and
cardiovascular involvement in chronic Chagas’ disease.
AHD exposure
The current use of AHDs was ascertained annually by
reviewing medication containers and/or physician pre-
scriptions during home visits to all of the participants. The
medications were coded on the basis of the Anatomical
Therapeutic Chemical/daily drug dose (ATC/DDD) classi-
fication system [23], and were considered AHDs if they fell
into ATC groups C02 (anti-hypertensives), C03 (diuretics),
C07 (beta-blockers), C08 (calcium channel blockers), or
C09 (agents acting on the renin-angiotensin system).
Time-varying AHD exposure was estimated by dividing
the follow-up into mutually exclusive periods of non-
use (no current or previous prescription), current use,
and stopped use (non-use after a previous prescription)
for each subject.
Blood pressure measurements
Systolic and diastolic BP were measured at baseline (1997),
and after three (2000), five (2002) and eleven (2008) years
of follow-up, using standard desk mercurial sphygmoma-
nometers (Welch Allyn Tycos 5097–30, Tycon, Arden,
USA) and stethoscopes (Littman Cardiology II, 3 M Med-
ical Devices, St. Paul, USA). Depending on the subject’s
right arm circumference, a standard (12×23 cm) or large
adult cuff size (15×32 cm) was used. At each time point,
three measurements separated by 2-minute intervals were
made after an initial 5-minute rest, and 30 minutes or
more after the last caffeine intake or last cigarette. The
measurements were made in the early morning in a quiet,
isolated, temperature-controlled room at the project field
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seated with the arm supported at heart level. The recorded
BP was the arithmetic mean of the second and third mea-
surements. Current BP was calculated by means of the lin-
ear interpolation of two consecutive measurements.Other variables
In addition to gender, age, educational level, conjugal sta-
tus and monthly family income (measured in number of
Brazilian minimum wages), we included baseline measures
of waist circumference, smoking (with current smokers
being defined as those who had smoked at least 100 ciga-
rettes during their lifetime and were still smokers), alcohol
consumption (with a high intake being defined as an aver-
age of more than two drinks per day for men and more
than one drink per day for women during the previous
12 months), history of coronary heart disease, self-rated
health (as assessed by the answer to the question “How
would you rate your own health?”), and plasma levels of
triglycerides, LDL-cholesterol, HDL-cholesterol, fasting
glucose, uric acid and C-reactive protein. The blood sam-
ples were drawn after a recommended 12-hour fast, and
the plasma measurements were made using standard en-
zymatic methods (Merck KgaA, Darmstadt, Germany).Statistical analysis
The data were fitted using interval Poisson models for un-
grouped person-time data [24]. To this end, an analytical
data set was constructed in which each subject contributed
multiple observations, each observation representing one
unit (a semester) of person-time. This approach avoided
the need to categorise the variables originally measured on
a continuous scale (such as the BP measurements) as well
as dynamically accommodated time-dependent variables.
The Poisson regression method is similar to Cox’s propor-
tional hazard regression analysis and produces equivalent
risk estimates [25], but is more suitable when working with
mortality rates rather than survival curves. Poisson models
directly estimate adjusted rate ratios (RRs) and make it
possible to obtain predicted mortality rates (MRs), thus
allowing the calculation of cumulative mortality rates
(CMRs) for the 11-year period. The two measures have
different meanings: the RRs and MRs indicate the force of
mortality, whereas the CMRs directly estimate the average
risk (probability) of death for a member of the cohort over
the period. Robust estimators of standard errors [26] were
used, and the models included terms for time-dependent
BP and age (both updated half-yearly), AHD exposure
(updated yearly), and all of the baseline variables men-
tioned above. As a preliminary separate analysis of men
and women did not reveal any substantial between-gender
differences, we subsequently pooled the data while keep-
ing gender as a control variable.The analyses were made using the Generalized Linear
Models procedure of Stata software, version 11.2 [27].
Results
Of the 1606 subjects enrolled, 1494 (93.0%) had their BP
measured at baseline and were included in the analysis.
Table 1 shows the baseline characteristics of the study
subjects.
The mean duration of follow-up was 8.7 years, and 574
deaths (of which 240 from CV causes) occurred. There
were few losses to follow-up during the eleven years from
1997 to 2007 (5.2%), leading to 13055.1 person-years (py)
of observation. The overall estimated CV MR was 18.2‰
py (95% confidence interval [95% CI]: 15.9-20.5‰ py).
Table 2 shows the observed CV deaths and person-
years at risk, and gives the estimated MRs and RRs (with
the AHD users as the reference group) stratified by sys-
tolic BP levels. The overall adjusted RR of CV mortality
estimated for the AHD stoppers was 3.12 (95% CI: 2.35-
4.15). The MRs were generally (but not significantly)
lower in the AHD non-users group compared with the
current users.
In order to clarify further the relationship between
mortality risk and systolic BP levels in the three AHD
exposure groups and evaluate interactions terms, we ran
the model including systolic BP as a continuous variable.
As simple graphic inspection of the raw data suggested a
non-linear relationship between MRs and systolic levels,
linear and quadratic terms for continuous BP levels were
included in the model. The quadratic terms were statis-
tically significant (p-values <0.02) in all of the three
groups. Figure 1 shows the CMRs obtained from the ex-
pected MRs and their 95% confidence intervals plotted
in relation to systolic BP levels. The CMRs indicate the
mean individual risk (or probability) of CV death over
the 11-year period. U-shaped curves (negative linear
terms and positive quadratic terms) related CV mortality
to systolic BP levels in all three exposure groups. The
subjects in the AHD users group had a 37.0% probability
of CV death if their systolic BP was 100 mmHg, the
CMR fell to 10.2% at 160 mmHg and then rose slowly to
15.7% at 190 mmHg, and a similar curve describes the
variation of the CV CMRs in the AHD non-users group.
However, the AHD stoppers had a 46.9% probability of
CV death if their systolic BP was 100 mmHg, a 36.7%
probability at 140 mmHg, and a 53.6% probability at
190 mmHg: the p-values for the interactions were 0.027
(linear term) and 0.045 (quadratic term).
Table 3 shows the CV mortality RRs of AHD stoppers vs
current users, estimated according to the duration of AHD
discontinuation and stratified by systolic BP levels. At the
lowest levels of BP, excess mortality occurred particularly
early after drug discontinuation, and the higher the BP
levels, the longer the duration of the discontinuation
Table 1 Baseline characteristics of the 1494 study subjects
Women, n(%) 908 (60.8)
Mean age, years (range) 69.1 (60–95)
Educational level < 4 years, n(%) 962 (64.4)
Conjugal status, n(%)
Married/live together 735 (49.2)
Never married 159 (10.6)
Divorced/separated 77 (5.2)
Widowed 523 (35.0)
Monthly family income*, n(%)
< 2 453 (30.3)
2 – 3.9 555 (37.2)
≥ 4 486 (32.5)




Low/moderate consumers 179 (12.0)
High consumers 143 (9.6)
History of coronary heart disease, n(%) 163 (10.9)
Self-rated health, n(%)




Mean waist circumference, cm (SD) 91.2 (11.1)
Mean LDL-cholesterol level, mg/dL (SD) 154.8 (44.9)
Mean glucose level, mg/dL (SD) 108.6 (43.3)
Median triglyceride level, mg/dL (IQ range) 130.0 (91.0-183.0)
Mean HDL-cholesterol level, mg/dL (SD) 49.2 (15.1)
Mean uric acid level, mg/dL (SD) 5.3 (1.7)
Median C-reactive protein level, mg/L (IQ range) 3.3 (1.5-6.7)
Anti-hypertensive drug use, n(%) 736 (49.3)
SD: standard deviation; IQ: interquartile.
*Measured in number of Brazilian minimum wages.
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fore, in those subjects exposed to AHD discontinuation
for longer than one year, there were clear increasing trends
of mortality risk across increasing levels of systolic BP.
Discussion
Hypertension is one of the leading clinical conditions af-
fecting the elderly; it increases their risk of cardiovascu-
lar, cerebrovascular and renal diseases, and requires
long-term treatment (often for an entire lifetime). It is
widely acknowledged that treating hypertension in the
elderly is important as it improves their quality of lifeand lowers the incidence of complications [28], but en-
suring the continuation of long-term drug therapy over
time is a considerable public health challenge, especially
among older people. Our findings indicate that, in com-
parison with their currently treated counterparts, elderly
subjects who discontinue AHDs are at three times
higher risk of death due to CV diseases.
The strength of our study mainly lies in its prospective
nature and the fact that it involved a large number of
community-dwelling elderly over a long period. As one of
its characteristics was its real-world context, the time-
dependent AHD exposure should reflect real clinical dy-
namics. The study is further strengthened by the fact that
the availability of repeated BP measurements allowed us
to adjust for the severity of hypertension and obtain opti-
mal estimates of individual current BP levels during the
follow-up period, thus overcoming the two problems of
indication and dilution biases. Unlike other studies that
have measured persistence with therapy using administra-
tive health databases [29], our data were based on the dir-
ect verification of drug containers and/or prescriptions,
and the uniformity of the data collection procedures as-
sures comparability between subjects. Nevertheless, given
that the data were collected annually, there may have been
some degree of non-differential misclassification of the
time of AHD exposure. Furthermore, we did not consider
medication-taking behaviour, understood as adherence to
the prescribed dosing regimens, and so it is possible that
some of the subjects classified as AHD users were not very
compliant. However, although such potential misclassifica-
tions can introduce a bias, it should always be in the direc-
tion of underestimating the effect [30]. It is moreover
worth noting that changes in public health policy (that
taken place during the study period) aiming to improve
access to medicines might have influenced the use and
persistence following prescription of AHDs.
Our analyses were extensively controlled for potential
confounding factors, including self-rated health. This vari-
able represents a key measure of health status and is a
well-established universal predictor of mortality [31]. The
perception of one’s own health is presumably an important
determinant of health-related behaviours. In the Bambuí
cohort population, the variable “self rated health” has been
found to be multidimensional in structure, reflecting so-
cioeconomic conditions, social support, health status and
access to/use of health services [32]. We don’t know the
specific reasons for treatment discontinuation; however, a
previous qualitative study of the beliefs and behaviour of
the hypertensive elderly people in the Bambuí cohort
showed that the absence of symptoms led many of them
to feel they were not ill and, accordingly, they underesti-
mated the importance of continuing to use their medica-
tions [33]. In addition, an ethno-epidemiological inquiry,
conducted with the aim of comprehending hypertension-
Table 2 Person-years (PY), cardiovascular deaths (CVd), estimated* cardiovascular mortality rates (CVR,‰ person-years)






Non-users Current users Stoppers
PY CVd CVR CVRR PY CVd CVR CVRR PY CVd CVR CVRR
< 120 1019.6 17 17.3 0.66 (0.36,1.22) 1070.1 32 26.2 1.00 257.1 21 60.6 2.31 (1.35,3.97)
120 - 139 1768.4 13 8.3 0.60 (0.31,1.16) 2854.6 39 13.8 1.00 615.6 30 37.5 2.72 (1.68,4.40)
140 - 159 770.3 4 5.7 0.62 (0.21,1.81) 2501.8 22 9.1 1.00 507.2 26 42.0 4.60 (2.59,8.16)
≥ 160 276.3 3 11.9 0.75 (0.22,2.59) 1239.5 20 15.9 1.00 174.6 13 60.8 3.84 (1.91,7.72)
Total 3834.6 37 10.0 0.67 (0.44,1.01) 7666.0 113 15.0 1.00 1554.5 90 46.7 3.12 (2.35,4.15)
*Using generalised linear Poisson model with a robust estimator of standard error. The model included terms for gender, time-dependent terms for age, systolic
blood pressure and AHD use, and terms for baseline educational level, conjugal status, monthly family income, smoking, alcohol consumption, history of coronary
heart disease, self-rated health, waist circumference, and plasma levels of LDL-cholesterol, glucose, triglycerides, HDL-cholesterol, uric acid and C-reactive protein.
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showed that conflicting cultural construction of “blood
pressure problems” contributed to non-adherence to treat-
ment [34]. Furthermore, a study of the reasons given by
Brazilian hypertensive patients for discontinuing pharma-
cological treatment showed that the most frequent was
the “normalisation” of BP, followed by the side effects of
the medications and forgetting to use them [35].
Deaths due to CV causes are likely to be complications
of hypertension. If cultural factors such as misconceptions
concerning symptoms underlie the decision to discontinue
AHDs, our results highlight the importance of providing
information/education in order to correct them. Further-
more, unlike the therapy stoppers, the current users had
only slightly increased CV CMRs even at the highest levels
of systolic BP, and this is of particular clinical and public
health concern as poor BP control rates have been found
in surveys of hypertensive patients in various countries












Figure 1 Cardiovascular cumulative mortality rates (CMR) and
95% confidence intervals by systolic blood pressure levels and
antihypertensive drug (AHD) exposure.resistant hypertension and faulty adherence to medication
has been stressed [37]. Our approach allowed us to make
a clear distinction between these different clinical contexts
and evaluate their associated CV mortality risks.
At the lowest levels of systolic BP, CV mortality was
relatively increased in all of our AHD exposure groups,
and it is possible that these deaths were related to ad-
vanced heart failure leading to low systolic BP, regardless
of whether the subjects were treated or not. It has been
previously suggested that the excess CV mortality re-
ported in elderly subjects with low BP is due to poor CV
health rather than the low BP itself [38]. This hypothesis
is supported by our results showing that much of the ex-
cess mortality at the lowest levels of systolic BP arise
early after AHD discontinuation.
The main purpose of allowing for the non-AHD users
group was to ensure that the comparison of interest
(AHD stoppers vs current users) has been made by in-
cluding only subjects for whom AHDs was prescribed,
therefore making it more meaningful. However, the risk
of CV mortality in the group of non-AHD users wasTable 3 Estimated*cardiovascular mortality rate ratios
(95% confidence interval) by systolic blood pressure






Duration of AHD discontinuation
< 1 year 1-2 years ≥ 2 years
<120 3.94 (2.12,7.35) 2.29 (0.82,6.41) 0.97 (0.35,2.66)
120 - 139 4.57 (2.53,8.25) 3.40 (1.53,7.54) 1.25 (0.55,2.80)
≥ 140 4.15 (2.19,7.88) 6.32 (3.35,11.93) 3.06 (1.64,5.69)
Total 4.27 (2.95,6.19) 4.11 (2.62,6.44) 1.75 (1.13,2.71)
*Using generalised linear Poisson model with a robust estimator of standard
error. The model included terms for gender, time-dependent terms for age,
systolic blood pressure and AHD use, and terms for baseline educational level,
conjugal status, monthly family income, smoking, alcohol consumption, history
of coronary heart disease, self-rated health, waist circumference, and plasma
levels of LDL-cholesterol, glucose, triglycerides, HDL-cholesterol, uric acid and
C-reactive protein. Current AHD users are the reference group.
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remember that this group included subjects for whom
pharmacological therapy was not indicated, either because
they were not hypertensive or because their hypertension
was clinically considered less severe, and so lifestyle modi-
fications may have been all that was necessary to reduce
the risk even at high BP levels. This hypothesis is indir-
ectly supported by the fact that there was a high preva-
lence of hypertension awareness at baseline (about 80%)
[9], and the cohort was subsequently well monitored.
Thus, it is presumable that the physicians recommended
lifestyle modifications instead of prescribing drug therapy
in absence of another risk factors or target organ damage.
Several mechanisms have been proposed to explain the
possible protective effect of lifestyle interventions against
CV diseases in the elderly, including a reduction of vulner-
ability. Thus, lifestyle practices (particularly physical activ-
ity and caloric restriction) could minimize the risk of
death from CV disease in older persons [39]. In this con-
cern, our results seem suggest that pharmacological treat-
ment could be not always necessary to reduce risk. On the
other hand, the findings regarding the stoppers suggest
that once AHDs were prescribed, they should not be dis-
continued, except on medical advice.
It has been institutionally recognised that lack of per-
sistence to long-term therapies is an international prob-
lem. Official recommendations to improve persistence
include supporting patients by means of tailored multi-
disciplinary interventions [40]. Our data highlight the
importance of cultural aspects, particularly the gap be-
tween objective and subjective judgements of the ser-
iousness of the disease, and suggest that hypertensive
patients should be helped to acquire appropriate percep-
tions concerning CV risk and the benefits of regularly
taking their prescribed medication.
Conclusion
Older subjects who discontinue the use of AHDs have a
three times higher risk of CV mortality than those con-
tinuing treatment. Our findings highlight the discontinu-
ation of pharmacological antihypertensive therapy in the
elderly as a major public health problem and suggest the
benefit of informative action aimed at giving older sub-
jects an appropriate perception of disease symptoms and
the related risk of complications.
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